Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For instance, the $18B estimate did not factor in government purchases for their national stockpiles. Previous governmental purchase orders for the Regeneron and Lilly mAbs were for potentially 1 million-plus doses of those products, according to an article by Fierce Pharma, which reported on the EUA awarded to GSK/Vir for their mAb, sotrovimab.
Of course you do and good luck with that thesis. You clearly don't understand how foreign governments work nor have you spent anytime looking at their drug paying history.
Another drug may join list of FDA-authorized COVID treatments
https://www.usatoday.com/story/news/health/2021/05/28/covid-memorial-day-cvs-vaccine-variant-mask-cdc/7477992002/
Biopharmaceutical company Humanigen submitted their drug Lenzilumab to the Food and Drug Administration for emergency use authorization to treat hospitalized patients with COVID-19, the company announced Friday.
If authorized, the drug will join a growing list of treatments authorized by the FDA for COVID-19. Lenzilumab focuses on preventing and treating an overactive immune response commonly known as a “cytokine storm,” which causes the immune system to kill both healthy and diseased tissue.
In a Phase 3 study, the drug improved the likelihood of survival without ventilation by 54% in newly hospitalized patients. Survival improved by 92% in patients who also took certain steroids and remdesivir.
“There is a need for hospitalized patients who require supplementary oxygen,” said Dr. Cameron Durrant, Humanigen’s chief executive officer. “Treatments can be lifesaving; despite vaccinations, infections and significant breakthrough disease will continue.”
“There is a need for hospitalized patients who require supplementary oxygen,” said Dr. Cameron Durrant, Humanigen’s chief executive officer. “Treatments can be lifesaving; despite vaccinations, infections and significant breakthrough disease will continue.”
So if serial shorters Einhorn and Finkle are doing their due diligence this weekend on their short position, please read these links. Lenzilumab is a game changer for Covid. It will be the Standard of Care for newly hospitalized Covid patients. And the CAR-T indication is even more exciting.
Lenzilumab is a GM-CSF inhibitor. The "M" in GM-CSF is macrophage.
CAR-T
https://www.nature.com/articles/s41408-021-00459-7
https://www.nature.com/articles/s41421-021-00255-4
https://www.targetedonc.com/view/lenzilumab-plus-axi-cel-achieves-responses-in-100-of-patients-with-dlbcl-with-limited-toxicity-in-small-study
https://www.healio.com/news/hematology-oncology/20210422/lenzilumab-before-cart-induces-high-response-rates-without-severe-toxicities
Covid
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
https://www.nature.com/articles/s41586-021-03569-1
https://www.pharmaceutical-technology.com/news/humanigen-lenzilumab-improves-survival/
HGEN Summary
https://www.reddit.com/r/Humanigen/comments/n1a4q4/another_awesome_dd/
Do some diligence... It's very simple Google Marc Cohodes --- and you'll find plenty to choose from.
Nobody is going to pay $10K per treatment. You're also assuming a very high number of hospitalizations get the treatment, which is not going to happen.
Marc Cohodoes, a big picture guy and he hasn't been very good at it for a long time? You have no idea what you're talking about. None... Google him and you will see a number of biotech he's successfully shorted and others he's done very well going long. I wouldn't be taking the other side of his trades. You on the other hand... I'll take it all day long.
People's vaccines will wear off like all the other vaccinations we've taken in our lives, right?
How is that a billion dollars of revenue? Please show your work.
The CDC data I was looking at was showing 3,000 total hospitalizations last week.
Haha... Now that's LMAO stuff. You have no idea what you're talking about.
Except its decline 10% per week... And how many vaccinated people have ended up in the hospital?
90K a month? Where did you learn how to do math... 3,100 per week x 4 weeks in a month = 12,400 per month and these numbers are dropping approximately 10% per week.
Hospitalizations were 3,100 last week
With the vast majority of Americans getting the vaccine, there is little to no need for HGEN's EUA in the U.S.
Now do Marc Cohodes, David Einhorn
I think we've known all along that getting the EUA is the real catalyst. They had already announced that they were going to apply for the EUA at the end of May so it was 100% already baked in.
I still didn't think that it was possible to drop 11% on the news. But it was perfect timing for a short attack. All of us know how screwed the shorts are right now because all of us have been learning about the science. It took me months of following this stock on a daily basis to understand the science enough to be confident that lenzilumab would get an EUA. And that was after being exclusively invested in Covid treatment stocks since March 2020. And I still wasn't totally sure until the Imperial College London trial results came out confirming that GM-CSF was the correct target to prevent severe Covid and death. That was what cinched it for me.
Shorts don't usually study their shorted stocks in detail. They have too much on their plate to focus on one stock. They are shorting HGEN because they have made a bunch of money shorting other Covid stocks. Most Covid treatments have failed their trials. And lenzilumab's 54% efficacy looks really good but not amazing on the surface. But lenzilumab's data is ridiculously good with newly hospitalized patients. For early and mid stage severe patients under 85yo, lenzilumab has 2.96-fold efficacy on its primary endpoint of preventing mechanical ventilation and 2.17-fold efficacy on preventing mortality. Those are homerun numbers with any trial but are truly amazing for hospitalized Covid patients. No other severe or critical Covid trials have produced even good data much less game changing data like lenzilumab.
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
Fun fact: Of ALL companies scanned on Fintel for a high short score squeeze rating ,CYDY is #33.
One nice thing about a low stock price is that it might help government officials give an EUA. Government officials must be jealous of the money that the private sector makes. They don't have much to be jealous of with HGEN.
Not releasing the pr until 30 minutes before market exacerbated the "buy the rumor, sell the news" component of this drop. It is a good buying opportunity.
I can't believe Nomis was selling at $14. What a dingleberry.
What are your qualifications to determine "The" correct mechanism for an immunomodulator? Are you say there can only be one correct mechanism?
And CYDY was 80% higher on April 19th than it is now.
VIR mc 6billion and there are already few other mild covid mabs that are currently under used
How many doses does a patient need?
At what point in the disease development exactly does the administering 'optimally' need to be done. Earlier in the time-lines = more doses needed because they will be administered preventively to a larger number of people that in the end (with hindsight) wouldn't have needed them.
If they ONLY care what drug down regulate GM-CSF , they be also ALL OVER leronlimab.
But they not....I wonder why..
Leronlimab wish they could copy lenzilumab protocol , but they couldn't , they didn't have Dr Fauci push with FDA.
The key difference between the studies is that CYDY did not take the time to craft their study. They CYDY decided on lumping both critical and severe patients together and using the combined results to generate a P value.
What CYDY was doing was gambling that the combined groups would generate enough data to claim statistical significance. The gamble did not pay of and CYDY scrambled to make claims their own study was not designed to outright prove.
Now the top holding in the $XBI
Just curious how many patients after receiving lenzilumab came a live off ECMO after 70 days on it
Lenzilumab is not as good as Leronlimab
This is a protocol for severe covid with lenzilumab , if you compare to our moderate protocol is the same except they excluding all patients with any secondary infections
The problem with VIR approval is exactly what you stated as not the problem., that drug works before lenz so it will decrease the severe population..
My guess is that we dropped today because of VIR getting an EUA yesterday. Lenzilumab isn't in competition with VIR's mab at all. VIR's mab is an anti-viral mab and is given early to non-hospitalized patients. Lenzilumab is an immunomodulator and is only given to hospitalized patients. Covid patients need both anti-viral treatment and immunomodulation.
Every time another Covid treatment drug gets an approval or gets good press, HGEN goes down. It doesn't matter that they aren't in competition at all. Lenzilumab is still the only treatment that has been shown to be effective with severe patients.
The bright side is that these unjustified drops in share price are temporary. Consider it a buying opportunity.
The Mayo Clinic has decided to officially change their name to The Habanero Aioli Clinic because lenzilumab is straight fire.